You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 18, 2024

ROZEREM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Rozerem patents expire, and what generic alternatives are available?

Rozerem is a drug marketed by Takeda Pharms Usa and is included in one NDA.

The generic ingredient in ROZEREM is ramelteon. There are three drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the ramelteon profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Rozerem

A generic version of ROZEREM was approved as ramelteon by DR REDDYS LABS SA on July 26th, 2013.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ROZEREM?
  • What are the global sales for ROZEREM?
  • What is Average Wholesale Price for ROZEREM?
Summary for ROZEREM
Drug patent expirations by year for ROZEREM
Drug Prices for ROZEREM

See drug prices for ROZEREM

Recent Clinical Trials for ROZEREM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Brigham and Women's HospitalPhase 4
Rhode Island HospitalPhase 4
State University of New York at BuffaloPhase 4

See all ROZEREM clinical trials

Pharmacology for ROZEREM
Paragraph IV (Patent) Challenges for ROZEREM
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ROZEREM Tablets ramelteon 8 mg 021782 2 2009-07-22

US Patents and Regulatory Information for ROZEREM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa ROZEREM ramelteon TABLET;ORAL 021782-001 Jul 22, 2005 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ROZEREM

See the table below for patents covering ROZEREM around the world.

Country Patent Number Title Estimated Expiration
Norway 983970 ⤷  Sign Up
Japan 2002212063 COPOLYVIDONE-CONTAINING PHARMACEUTICAL PREPARATION ⤷  Sign Up
Hong Kong 1087112 ⤷  Sign Up
Hungary 224220 Triciklusos vegyületek, eljárás előállításukra és alkalmazásuk (TRICYCLIC COMPOUNDS, THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS AND USE) ⤷  Sign Up
Australia 2231897 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.